Special Issue

Pharmacoepidemiology and Addiction

Message from the Guest Editor

Substance use remains a significant public health concern worldwide. Pharmacoepidemiologic studies are a critical component in mitigating adverse outcomes across the addiction spectrum. Understanding trends in drug use, particularly the detection of novel psychoactive substances, provides opportunities for prevention and intervention. This Special Issue on aims to keep up to date on current or shifting trends in substance use, the identification of novel psychoactive substances, the development of novel pharmacologic treatments for mono- or polysubstance use, outcome research for currently established pharmacologic treatments of addiction, the integration of pharmacologic treatments for comorbid conditions into addiction medicine, and the development of pharmacologic interventions for drug overdose or other adverse outcomes. This issue will accept original research articles, review articles, commentaries, letters or other materials facilitating an understanding of addiction through pharmacoepidemiology.

Guest Editor

Dr. Matthew Ellis Department of Psychiatry, Washington University in St. Louis, School of Medicine, St.Louis, MO, USA

Deadline for manuscript submissions

closed (31 December 2023)



Pharmacoepidemiology

an Open Access Journal by MDPI



mdpi.com/si/103075

Pharmacoepidemiology MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 pharmacoepidemiology@mdpi.com

mdpi.com/journal/ pharmacoepidemiology





Pharmacoepidemiolog

an Open Access Journal by MDPI



pharmacoepidemiology

About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Dr. Carlotta Franchi Department of Health Policy, Head of Laboratory of Pharmacoepidemiology and Human Nutrition, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 22.7 days after submission; acceptance to publication is undertaken in 6.3 days (median values for papers published in this journal in the first half of 2024).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names published annually in the journal.

